Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review

Simple item page
dc.contributor.authorTan, S.
dc.contributor.authorDay, D.
dc.contributor.authorNicholls, S.J.
dc.contributor.authorSegelov, E.
dc.date.issued2022
dc.description.abstractImmune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that have significantly improved the prognosis of various cancers, both in (neo)adjuvant and metastatic settings. Unlike other conventional therapies, ICIs elicit antitumor effects by enhancing host immune systems to eliminate cancer cells. There are 3 approved ICI classes by the U.S. Food and Drug Administration: inhibitors targeting cytotoxic T lymphocyte associated antigen 4, programmed death 1/programmed death-ligand 1, and lymphocyte-activation gene 3, with many more in development. ICIs are commonly associated with distinct toxicities, known as immune-related adverse events, which can arise during treatment or less frequently be of late onset, usually relating to excessive activation of the immune system. Acute cardiovascular immune-related adverse events such as myocarditis are rare; however, data suggesting chronic cardiovascular sequelae are emerging. This review presents the current landscape of ICIs in oncology, with a focus on important aspects relevant to cardiology.
dc.description.statementofresponsibilitySean Tan, Daphne Day, Stephen J. Nicholls, Eva Segelov
dc.identifier.citationJACC. CardioOncology, 2022; 4(5):579-597
dc.identifier.doi10.1016/j.jaccao.2022.09.004
dc.identifier.issn2666-0873
dc.identifier.issn2666-0873
dc.identifier.orcidNicholls, S.J. [0000-0002-9668-4368]
dc.identifier.urihttps://hdl.handle.net/2440/137408
dc.language.isoen
dc.publisherElsevier BV
dc.relation.grantNHMRC
dc.rights© 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.source.urihttps://doi.org/10.1016/j.jaccao.2022.09.004
dc.subjectbiomarkers; cardio-oncology; cardiotoxicity; immune checkpoint inhibitors; immune related adverse events; immunotherapy; medical oncology
dc.titleImmune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_137408.pdf
Size:
3.56 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications